Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
259 results about "Fibronectins" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins.
Secretion signal vectors
InactiveUS7071172B2Minimize potential deleterious side effectAttenuate seizure activityBiocideAnimal repellantsHeterologousAdeno associate virus
The present invention provides delivery vectors for transferring a nucleic acid sequence to a cell in vitro, ex vivo or in vivo. The delivery vector comprises a segment encoding a secretory signal peptide. In embodiments of the invention, the delivery vector is an adeno-associated virus (AAV) vector. In other embodiments, the secretory signal peptide is a fibronectin secretory signal peptide (including variations and modifications, thereof). The delivery vectors of the invention may further comprise a heterologous nucleic acid sequence encoding a polypeptide of interest for transfer to a target cell, where the polypeptide of interest is operably associated with the secretory signal. Also disclosed are methods of transferring a nucleic acid of interest to a cell using the delivery vectors of the invention.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL
Artificial antibody polypeptides
A fibronectin type III (Fn3) polypeptide monobody, a nucleic acid molecule encoding a monobody, and a variegated nucleic acid library encoding a monobody, are provided by the invention. Also provided are methods of preparing an Fn3 polypeptide monobody, and kits to perform such methods. Further provided is a method of identifying the amino acid sequence of a polypeptide molecule capable of binding to a specific binding partner (SBP) so as to form a polypeptide:SSP complex, and a method of identifying the amino acid sequence of a polypeptide molecule capable of catalyzing a chemical reaction with a catalyzed rate constant, kcat, and an uncatalyzed rate constant, kuncat, such that the ratio of kcat / kuncat is greater than 10.
Owner:NOVARTIS AG
Improved fibronectin-based binding molecules and uses thereof
InactiveUS20110038866A1Simple and efficientProlong lifePeptide/protein ingredientsAntibody mimetics/scaffoldsHalf-lifeFibronectins
The invention provides fibronectin type III (Fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific Fn3-based binding molecules that bind to two or more targets simultaneously. The Fn3-based binding molecules of the invention can also be linked together to form multispecific Fn3-based binding molecules, and / or can be conjugated to a non-Fn3 moiety, such as, Human Serum Albumin (HSA), for improved half life and stability. The invention also provides methods for generating, screening and using Fn3-based binding molecules in a variety of therapeutic and diagnostic applications.
Owner:NOVARTIS AG
Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
InactiveUS20070005261A1Rapidly and accurately determinedMaximal sensitivityMedical data miningDisease diagnosisStroke subtypeBiomarker (petroleum)
Methods for the diagnosis and evaluation of stroke and stroke sub-type employ a variety of bio-markers including cellular fibronectin (c-Fn) assembled as a panel for stoke diagnosis and evaluation. Methods are disclosed for selecting markers and correlating their combined levels with a clinical outcome of interest. In various aspects the methods permit early detection and differentiation of stroke subtypes, determination of the prognosis of a patient presenting stroke symptoms, and identification of a patient at risk for early hematoma growth and / or malignant massive cerebral artery infarction. The disclosed methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and to reduce the human and economic costs associated with incorrect stroke diagnosis.
Owner:PREDICTION SCI
Serum-free culture medium for mesenchymal stem cells
ActiveCN102827807AAvoid instabilityClear chemical compositionSkeletal/connective tissue cellsCell phenotypeSodium bicarbonate
The invention relates to the field of biology, and discloses a serum-free culture medium which essentially comprises an IMDM (Iscove Modified Dulbecco Medium), L-glutamine, sodium bicarbonate, Hepes, recombinant human insulin, recombinant human transferrin, recombinant human albumin, 2-mercaptoethanol, protocatechuic acid, lipid, amino acid, vitamins, trace elements, Pluronic F-68, hydrocortisone, vitamin C, bonding amine or recombinant human fibronectin, progesterone, putrescine, heparin, serotonin, epidermal growth factors (EGFs), b-fibroblast growth factors (FGF), platelet derive growth factor (PDGF)-BB and insulin-like growth factor (IGF)-I. The serum-free culture medium is clear in chemical components, free from animal sources and serum and safe and ideal in cell cultivation and avoids the doped animal components and unstable batches, and the results of the cultured mesenchymal stem cells show that the total cellular score, the cell phenotype and the secretory cell factors are normal, so that the serum-free culture medium has good industrial application prospect.
Owner:内蒙古干细胞医学工程技术研究中心
Universal fibronectin type iii bottom-side binding domain libraries
The invention pertains to a natural-variant combinatorial library of fibronectin Type 3 domain (Fn3) polypeptides useful in screening for the presence of one or more polypeptides having a selected binding or enzymatic activity. The library polypeptides include (a) regions A, AB, B, C, CD, D, E, EF, F, and G having wildtype amino acid sequences of a selected native fibronectin Type 3 polypeptide or polypeptides, and (b) loop regions AB, CD, and EF having selected lengths (Bottom Loops). The Fn3 may also have loop regions BC, DE, and FG having wildtype amino acid sequences, having selected lengths, or mutagenized amino acid sequences (Top Loops).
Owner:NOVARTIS AG
Fibronectin binding protein compositions and methods of use
InactiveUS6685943B1Avoid problemsOvercomes drawbackPeptide/protein ingredientsAntibody mimetics/scaffoldsPassive ImmunizationsStreptococcus pyogenes
Disclosed are antibodies that block the binding of fibronectin protein to fibronectin. Also disclosed are site specifically-mutated and truncated peptide epitopes derived from the fnbA and fnbB genes of Staphylococcus aureus, the fnba and fnbB genes of Streptococcus dysgalactiae, and the sfb gene of Streptococcus pyogenes, and nucleic acid segments encoding these peptides and epitopes. The anti-(fibronectin binding site) antibodies, peptides and epitopes that give rise to antibodies that block the binding of fibronectin binding proteins to fibronectin, and DNA segments encoding these proteins and are of use in various screening, diagnostic and therapeutic applications including active and passive immunization and methods for the prevention of streptococcal and staphylococcal colonization in animals or humans. These. DNA segments and the peptides derived therefrom are proposed to be of use directly in the preparation of vaccines and also for use as carrier proteins in vaccine formulations.
Owner:UNIVERSITY OF MANITOBA +2
Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ActiveUS20110201038A1Easy to adaptMicrobiological testing/measurementDisease diagnosisInterleukin 10Soluble P-Selectin
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, S100-A12, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-1 receptor antagonist, Interleukin-1 beta, Interleukin-10, Interleukin-15, Interleukin-3, Myeloperoxidase, Nidogen-1, soluble Oxidized low-density lipoprotein receptor 1, Pappalysin-1, soluble P-selectin glycoprotein ligand 1, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinase 1, Tissue inhibitor of metalloproteinase 2, soluble Tumor necrosis factor, soluble Vascular cell adhesion molecule 1, and Vascular endothelial growth factor A as diagnostic and prognostic biomarkers in renal injuries.
Owner:ASTUTE MEDICAL
Reconstituted polypeptides
InactiveUS20130237684A1Connective tissue peptidesPeptide/protein ingredientsFibronectinsNucleic acid molecule
Owner:RES CORP TECH INC
Multi-well micropatterning by ablation
InactiveUS20080220516A1Without increasing experimental complexitySolve the practicality is not highBioreactor/fermenter combinationsSequential/parallel process reactionsMatrigelAlternative methods
The present invention is drawn to the generation of micropatterns of biomolecules and cells on standard laboratory materials through selective ablation of a physisorbed biomolecule with oxygen plasma. In certain embodiments, oxygen plasma is able to ablate selectively physisorbed layers of biomolecules (e.g., type-I collagen, fibronectin, laminin, and Matrigel) along complex non-linear paths which are difficult or impossible to pattern using alternative methods. In addition, certain embodiments of the present invention relate to the micropatterning of multiple cell types on curved surfaces, multiwell plates, and flat bottom flasks. The invention also features kits for use with the subject methods.
Owner:MASSACHUSETTS INST OF TECH
Choline binding proteins for anti-pneumococcal vaccines
InactiveUS6245335B1Improve efficiencySufficient quantityAntibacterial agentsBacteriaBacteroidesCholine binding protein
The invention relates to bacterial choline binding proteins (CBPs) which bind choline. Such proteins are particularly desirable for vaccines against appropriate strains of Gram positive bacteria, particularly streptococcus, and more particularly pneumococcus. Also provided are DNA sequences encoding the bacterial choline binding proteins or fragment thereof, antibodies to the bacterial choline binding proteins, pharmaceutical compositions comprising the bacterial choline binding proteins, antibodies to the bacterial choline binding proteins suitable for use in passive immunization, and small molecule inhibitors of choline binding protein mediated adhesion. Methods for diagnosing the presence of the bacterial choline binding protein, or of the bacteria, are also provided. In a specific embodiment, a streptococcal choline binding protein is an enolase, which demonstrates strong affinity for fibronectin.
Owner:THE ROCKEFELLER UNIV
Fibronectin based scaffold domain proteins that bind to myostatin
ActiveUS8853154B2Inhibitory activityIncrease volumeBacteriaPeptide/protein ingredientsMyostatinFibrosis
Owner:BRISTOL MYERS SQUIBB CO
Methods and compositions for wound healing
InactiveUS6025150APeptide/protein ingredientsMammal material medical ingredientsDeep woundsChronic wound
Assays employing fibronectin-depleted substrates are described to identify invasion inducing agents. Such agents are useful for in vivo wound healing, including but not limited to deep wounds and chronic wounds.
Owner:MICHIGAN UNIV OF RGT THE
Preparation method of human cytokine-induced killer cells
InactiveCN102732481APromote proliferationRaise the ratioBlood/immune system cellsHybrid peptidesPeripheral blood mononuclear cellCytotoxicity
The invention discloses a preparation method of human cytokine-induced killer cells, comprising the following steps: coating a cell culture flask with a coating buffer containing effective amount of fusion protein and human CD3 monoclonal antibody before culturing precursor cells of human CIK cells, and adding the human CD3 monoclonal antibody in the whole process of inducing and culturing the human CIK cells, wherein the fusion protein is human intercellular adhesion molecule-1 functional domain and human fibronectin functional domain fusion protein, and the concentration of the human CD3 monoclonal antibody in the cell culture solution is lower than the concentration of the human CD3 monoclonal antibody in the coating buffer. According to the invention, ex-vivo expansion efficiency of peripheral blood mononuclear cells and the proportion of CD3 / CD56 double positive cells in the CIK cells are significantly raised, the cytotoxicity activity of the CIK cells is enhanced, thus the effect of cellular immunity treatment is raised.
Owner:SHENZHEN YOUNGCELL BIO TECH
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
InactiveUS20030008816A1Improve complianceFunction increaseAntibacterial agentsCosmetic preparationsCell adhesionPulmonary compliance
The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.
Owner:CC10 SWEDEN +4
Methods for retroviral mediated gene transfer employing molecules, or mixtures thereof, containing retroviral binding domains and target cell binding domains
InactiveUS6472204B1Efficient and convenient methodGood choiceAntibody mimetics/scaffoldsGenetic material ingredientsCell bindingDNA-binding domain
Owner:TAKARA HOLDINGS
Combination products with carboxylic acid derivatives that inhibit the binding of integrins to their receptors and other therapeutic compounds
A composition, method and kit comprising a compound for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin and other therapeutic compounds for the control or prevention of diseases states in which α4β1 is involved.
Owner:ENCYSIVE PHARMA INC +1
Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
A method for the inhibition of the binding of α4β1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which α4β1 is involved.
Owner:ENCYSIVE PHARMA INC
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
InactiveUS20020169108A1Improve complianceFunction increaseCosmetic preparationsCell receptors/surface-antigens/surface-determinantsCell adhesionVascular endothelium
The present invention provides methods and compositions to treat fibrotic conditions, to increase lymphocyte production in vivo, and to improve and / or normalize lung function, pulmonary compliance, blood oxygenation, and blood pH to inhibit inflammatory processes to stimulate or inhibit pro-inflammatory and immune cells, and to inhibit migration of vascular endothelial cells. The invention contemplates the administration of human uteroglobin, native or recombinant, as a means of achieving these ends. Specifically, it has been found that uteroglobin inhibits cell adhesion to fibronectin, increases lymphocyte production in vivo, and improves and / or normalizes lung function, pulmonary compliance, blood oxygenation, and blood pH, and inhibits inflammatory process. In addition it has been found that uteroglobin can stimulate or inhibit pro-inflammatory and immune cells and inhibitor migration of vascular endothelial cells.
Owner:CC10 SWEDEN
Anticancer compounds and methods
InactiveUS20060078535A1Inhibit tumor invasionInhibit growthPeptide/protein ingredientsNanomedicineLymphatic SpreadHuman tumor
The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described including non-peptide compositions of matter.
Owner:RGT UNIV OF MICHIGAN
Biological tissue matrix material, and preparation method and purpose thereof
ActiveCN107007886AImprove processing efficiencyHigh bonding strengthTissue regenerationProsthesisFiberCell-Extracellular Matrix
The invention provides a biological tissue matrix material, and a preparation method and a purpose thereof. The biological tissue matrix material is characterized by comprising an extracellular matrix, wherein the extracellular matrix comprises collagenous fiber, growth factors and fibronectin. The biological tissue matrix material is prepared from small intestinal submucosa matrix materials. The preparation method is characterized by comprising the following steps that decellularization is performed: decellularized liquid contains trypsin and PBS solution, and also contains EDTA, EDTA-2Na or EDTA-4Na; the decellularized liquid is used for treatment in multi-frequency ultrasonic environment for decellularization; the dual-frequency ultrasound at least contains two ultrasonic frequencies with different frequencies. The decellularization process technology is improved; the DNA residual quantity of the obtained product is lower; the immunogenicity is lower; the anti-infection capability is higher; the restoration capability is higher.
Owner:BEIJING BIOSIS HEALING BIOLOGICAL TECH
Antibodies to the ED-B domain of fibronectin, their construction and uses
InactiveUS7273924B1High expressionEasy to detectOrganic active ingredientsBacteriaCancer researchFibronectin
A specific binding member is specific for and binds directly to the ED—B oncofoetal domain of fibronectin (FN).
Owner:PHILOGEN SRL LLC
Transglutaminase Crosslinked Collagen Biomaterial for Medical Implant Materials
InactiveUS20080305517A1Enhanced ability to support cell attachment cellEnhanced ability to support attachmentBone implantTissue cultureCross-linkMicroorganism
The present invention provides a method for producing an improved biomaterial comprising treating a collagen biomaterial with a transglutaminase under conditions which permit the formation of cross-links within the collagen. Preferably, the transglutaminase is a tissue transglutaminase, a plasma transglutaminase or a microbial transglutaminase. In a preferred embodiment, the collagen biomaterial further comprises a cell adhesion factor, such as fibronectin. The invention further provides biomaterials obtainable by the methods of the invention, and medical implants and wound dressings comprising the same.
Owner:ASTON UNIV
Preparation method and kit of bispecific chimeric antigen receptor gene modified natural killer cells
InactiveCN105647873ACell receptors/surface-antigens/surface-determinantsMammal material medical ingredientsNatural Killer Cell Inhibitory ReceptorsAntigen receptors
The invention provides a preparation method of bispecific chimeric antigen receptor gene modified natural killer cells, comprising the features: constructing a bispecific chimeric antigen receptor gene containing specific-binding signaling lymphocyte activation molecule family member 7 and fibronectin mutants, recombining the bispecific chimeric antigen receptor gene to a viral vector, transfecting with human natural killer cells, and highly expressing the bispecific chimeric antigen receptor gene, thus specifically binding tumor cells that express the signaling lymphocyte activation molecule family member 7 and fibronectin mutants, inhibiting expression of natural killer cell inhibitory receptors, and preventing immune escape of tumor cells; meanwhile, activating a first signal and a co-stimulatory signal to trigger toxic activity of the tumor cells, and great anti-tumor killing toxicity is shown in in-vivo and in-vitro experiments; the invention also provides a kit for the preparation of autologous natural killer cells through the above method, and with the kit, it is possible to highly express the bispecific chimeric antigen receptor gene and trigger great anti-tumor effect.
Owner:ZICHENG RUISHENGHUI BEIJING BIOTECH DEV CO LTD
Tissue engineering scaffold containing alginate, glycosaminoglycan and collagen and preparation method thereof
The invention belongs to the tissue engineering scaffold field and particularly provides a tissue engineering scaffold containing alginate, glycosaminoglycan and collagen and a preparation method thereof. The tissue engineering scaffold provided by the invention is prepared by the following raw materials by weight percent: 5-30% of chitosan, 5-30% of collagen, 5-30% of alginate, 0.1-3% of hyaluronic acid, 0.01-0.05% of crosslinking agent, 0.1-3% of chondroitin sulfate, 5-20% of polyvinyl alcohol and the balance tertiary distilled water. For optimization, the tissue engineering scaffold also contains a proper amount of cell growth factor, fibronectin and laminin. The tissue engineering scaffold can be processed and shaped and can be used to prepare products with different forms and thickness, the shaping method is easy to operate, the raw materials are easy to get and not expensive and the tissue engineering scaffold can be used for scale industrialized production.
Owner:JINAN UNIVERSITY
A kind of bladder cancer quantitative detection test paper
The invention relates to a test paper for quantitative detection of bladder cancer, which is composed of a sample pad, a colloidal gold pad, a nitrocellulose membrane, an absorbent paper and a bottom plate. On the nitrocellulose membrane, there is a detection area fixed with urinary fibronectin and sheep antibody. In the control area of the mouse secondary antibody, there is a gold-labeled anti-urinary fibronectin antibody on the colloidal gold pad, wherein the gold-labeled antibody is dispersed on the colloidal gold pad after being dispersed in a pH 5-10 dilution. The sensitivity of quantitative detection is up to 10ng / mL, the linear range is from 10-3000ng / mL, and it has the advantages of strong specificity, high precision, good stability, easy operation, low cost, etc. It is suitable for primary screening and surgical treatment of bladder cancer. After tracking.
Compositions and methods for producing bioactive fusion proteins
Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.
Owner:AMGEN INC
Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
ActiveUS20130011334A1Without decreasing overall stabilityIncrease the number ofBacteriaPeptide/protein ingredientsUbiquitin-Protein LigasesActive component
Owner:NAVIGO PROTEINS GMBH
A polymer film material and a preparation method thereof
ActiveCN103816816AAchieve adhesionStrong adhesionSemi-permeable membranesFunctional monomerAttachment protein
The invention provides a polymer film material and a preparation method thereof. The polymer film material comprises a hydrophobic polymer layer and a hydrophilic polymer layer. The hydrophilic polymer layer is provided with a hydrophilic adhesive area provided with a functional material fixed to fibronectin. The hydrophilic polymer layer is provided with through holes. The through holes and the hydrophobic polymer layer form a hydrophobic adhesive area. The functional material is a functional monomer or a polymer of the functional monomer. A method of adopting combination of surface grafting and controlled irradiation by utilizing a photomask is adopted, the hydrophilic adhesive area and the hydrophobic adhesive area are formed on the surface of the polymer film and erythrocyte attachment proteins are bonded in the hydrophilic adhesive area, thus obtaining the polymer film material used for separating a single erythrocyte and a single blood platelet from blood.
Owner:CHANGCHUN INST OF APPLIED CHEMISTRY - CHINESE ACAD OF SCI
Fibronectin-modified ecm tissue graft constructs and methods for preparation and use thereof
InactiveUS20070184122A1Organic active ingredientsPeptide/protein ingredientsCell-Extracellular MatrixFibronectin binding
Described are modified submucosa and other extracellular matrix materials incorporating an amount of bound, exogenous fibronectin. Further described are such materials also having an amount of exogenous heparin bound to the exogenous fibronectin, and also potentially an amount of an exogenous bioactive material, such as a growth factor, bound to the exogenous heparin. Such materials may be used in methods for the treatment of wounds in patients.
Owner:COOK BIOTECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com